MedAssets Shares Jumped: What You Need to Know (MDAS)

MedAssets Shares Jumped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of medical product maker MedAssets (Nasdaq: MDAS ) was miraculously cured today, sending the stock 19% higher.

So what: Revenue grew 50% to $143.7 million and adjusted earnings per share increased a penny to $0.26 per share. Analysts were only expecting revenue of $137.6 million and earnings per share of $0.17, so the results crushed what the "experts" thought.

Now what: When you take out the acquisition of Broadlane, the results aren't quite as eye-popping with adjusted revenue increasing only 2.5%. Nevertheless, beating expectations is always a welcome sight, and with shares trading at just 11 times forward earnings estimates, it looks like there's plenty of upside. MedAssets has now beaten estimates the last three quarters, and I think shares have more room to run.

Interested in more info on MedAssets? Add it to your watchlist by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.